Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

This study is comparing two treatment approaches for previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL): one where venetoclax is given continuously alongside acalabrutinib, versus one where venetoclax is given in on/off cycles to potentially reduce side effects while maintaining effectiveness. **You may be eligible if...** - You are 18 or older with a confirmed new diagnosis of CLL or SLL that requires treatment - You have never been treated for CLL or SLL before - Your general health is good enough to participate (ECOG score 0, 1, or 2) - Your kidney, liver, and blood counts meet minimum thresholds **You may NOT be eligible if...** - You have previously received any treatment for CLL or SLL - You are pregnant or breastfeeding - You have certain heart rhythm problems or significant organ dysfunction - You are on certain medications that interact with the study drugs Talk to your doctor to see if this trial is right for you.